Abu Raghavan Srinivasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Abu Raghavan Srinivasan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ananda Vayaravel Cassinadane
Sri Venkateshwaraa College of Paramedical Sciences, Ariyur, Puducherry, India
2 shared publications Radhika Govindarajan
2 shared publications- Ramesh Ramasamy
Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND
2 shared publications - Saidaiah Ikkurthi
AIIMS, Mangalagiri
2 shared publications Desai Vidya Sripad
1 shared publication- Desai Vidya Sripad
Department of Biochemistry, All India Institute of Medical Sciences, Mangalagiri, Guntur, Andhra Pradesh, India
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in Research Square
Intelectin-1 (ITLN1) Val109Asp (rs2274907) polymorphism: Association with circulating Omentin-1 Levels and Metaflammation in Men with Type 2 Diabetes
Aim Omentin-1 is an adipokine associated with insulin sensitivity and inflammatory processes, while the ITLN1 Val109Asp (rs2274907) variant has been implicated in metabolic phenotypes. We investigated its association with circulating omentin-1 and a metaflammatory phenotype in men with type 2 diabetes mellitus (T2DM). Methods In this cross-sectional study, 225 men with T2DM were genotyped for ITLN1 Val109Asp (TT, AT, and AA). Anthropometric, glycaemic, insulin-resistance, lipid, inflammatory, and haematological parameters were compared across genotypes. Associations between circulating omentin-1 and metabolic, inflammatory, and haematological parameters were assessed using Spearman correlation. Logistic regression evaluated associations between the variant and obesity under dominant, recessive, and additive models. Receiver operating characteristic analysis assessed discrimination of low circulating omentin-1. Results Omentin-1 concentrations decreased progressively from TT to AT to AA genotypes [749.6, 627.9, and 483.2 ng/L, respectively; P < 0.001], whereas BMI, HOMA-IR, METS-IR, lipid abnormalities, and inflammatory markers showed less favourable profiles in the AA group. Genotype and allele distributions differed across BMI phenotypes (P = 0.027 and P = 0.002, respectively). Omentin-1 was inversely correlated with BMI, WHR, HOMA-IR, and METS-IR and positively correlated with QUICKI across genotype groups. Each additional A allele was associated with higher odds of obesity (age-adjusted OR 1.97, 95% CI 1.27–3.05; P = 0.002). IL-8 showed the highest discrimination for low omentin-1 (AUC 0.976, 95% CI 0.959–0.992). Conclusion ITLN1 Val109Asp was associated with circulating omentin-1 concentrations and a metaflammatory phenotype in men with T2DM, linking genetic variation with a metabolic–inflammatory profile.
- 5 October 2026
- Published by Springer Nature in Research Square
Open AccessIntelectin-1 (ITLN1) Val109Asp (rs2274907) polymorphism: Association with circulating Omentin-1 Levels and Metaflammation in Men with Type 2 Diabetes
Aim Omentin-1 is an adipokine associated with insulin sensitivity and inflammatory processes, while the ITLN1 Val109Asp (rs2274907) variant has been implicated in metabolic phenotypes. We investigated its association with circulating omentin-1 and a metaflammatory phenotype in men with type 2 diabetes mellitus (T2DM). Methods In this cross-sectional study, 225 men with T2DM were genotyped for ITLN1 Val109Asp (TT, AT, and AA). Anthropometric, glycaemic, insulin-resistance, lipid, inflammatory, and haematological parameters were compared across genotypes. Associations between circulating omentin-1 and metabolic, inflammatory, and haematological parameters were assessed using Spearman correlation. Logistic regression evaluated associations between the variant and obesity under dominant, recessive, and additive models. Receiver operating characteristic analysis assessed discrimination of low circulating omentin-1. Results Omentin-1 concentrations decreased progressively from TT to AT to AA genotypes [749.6, 627.9, and 483.2 ng/L, respectively; P < 0.001], whereas BMI, HOMA-IR, METS-IR, lipid abnormalities, and inflammatory markers showed less favourable profiles in the AA group. Genotype and allele distributions differed across BMI phenotypes (P = 0.027 and P = 0.002, respectively). Omentin-1 was inversely correlated with BMI, WHR, HOMA-IR, and METS-IR and positively correlated with QUICKI across genotype groups. Each additional A allele was associated with higher odds of obesity (age-adjusted OR 1.97, 95% CI 1.27–3.05; P = 0.002). IL-8 showed the highest discrimination for low omentin-1 (AUC 0.976, 95% CI 0.959–0.992). Conclusion ITLN1 Val109Asp was associated with circulating omentin-1 concentrations and a metaflammatory phenotype in men with T2DM, linking genetic variation with a metabolic–inflammatory profile.
- Open Access
- 11 September 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 137
Single Point Insulin Sensitivity Estimator (SPISE), a novel score to evaluate insulin sensitivity, is predictive in anthropometry specified adults with type 2 diabetes mellitus
Purpose: The study was aimed at the assessment of non-insulin-based markers as alternatives to the conventional insulin-based indices in anthropometry specified type 2 Diabetes mellitus. The outcome was targeted towards the utility of such indices in diabetes mellitus and associated metabolic derangements centering around insulin resistance. Methods: Fasting venous blood samples were utilized for biochemical analyses. The parameters included plasma glucose, insulin, lipid profile [triglycerides, HDL cholesterol, total cholesterol and LDL cholesterol (Friedewald equation)]. Uric acid, liver enzymes, renal profile, electrolytes, and thyroid function tests were also evaluated. Appropriate statistical analysis, as deemed fit for normal and skewed data were undertaken. Results: Across the BMI categories, significant differences were observed in several insulin-resistance indices. Quantitative Insulin Sensitivity Check Index (QUICKI) values were lowest in the obese group and highest in the normal-weight group ( p < 0.0001). Single Point Insulin Sensitivity Estimator (SPISE) values also showed reduction across normal, overweight, and obese groups ( p < 0.0001). The TyG index demonstrated a significant increase with rising BMI ( p = 0.0002). With reference to utility of SPISE as a predictor in anthropometry specified groups, it demonstrated a near-perfect discriminatory performance with an AUC of 0.99 (95% CI: 0.97–1.00, p < 0.0001). A cut-off value of < 5.55 yielded a sensitivity of 92.5% and specificity of 93.3%. Conclusions: SPISE, independent of insulin, showed high discrimination of BMI-defined obesity in this T2DM cohort, although its performance should be interpreted cautiously because BMI is incorporated into the SPISE equation.
- 11 September 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 137
Open AccessSingle Point Insulin Sensitivity Estimator (SPISE), a novel score to evaluate insulin sensitivity, is predictive in anthropometry specified adults with type 2 diabetes mellitus
Purpose: The study was aimed at the assessment of non-insulin-based markers as alternatives to the conventional insulin-based indices in anthropometry specified type 2 Diabetes mellitus. The outcome was targeted towards the utility of such indices in diabetes mellitus and associated metabolic derangements centering around insulin resistance. Methods: Fasting venous blood samples were utilized for biochemical analyses. The parameters included plasma glucose, insulin, lipid profile [triglycerides, HDL cholesterol, total cholesterol and LDL cholesterol (Friedewald equation)]. Uric acid, liver enzymes, renal profile, electrolytes, and thyroid function tests were also evaluated. Appropriate statistical analysis, as deemed fit for normal and skewed data were undertaken. Results: Across the BMI categories, significant differences were observed in several insulin-resistance indices. Quantitative Insulin Sensitivity Check Index (QUICKI) values were lowest in the obese group and highest in the normal-weight group ( p < 0.0001). Single Point Insulin Sensitivity Estimator (SPISE) values also showed reduction across normal, overweight, and obese groups ( p < 0.0001). The TyG index demonstrated a significant increase with rising BMI ( p = 0.0002). With reference to utility of SPISE as a predictor in anthropometry specified groups, it demonstrated a near-perfect discriminatory performance with an AUC of 0.99 (95% CI: 0.97–1.00, p < 0.0001). A cut-off value of < 5.55 yielded a sensitivity of 92.5% and specificity of 93.3%. Conclusions: SPISE, independent of insulin, showed high discrimination of BMI-defined obesity in this T2DM cohort, although its performance should be interpreted cautiously because BMI is incorporated into the SPISE equation.
- Open Access
- 1 March 2018
- Published by Pharmamedix India Publication Pvt Ltd in Asian Journal of Medical Sciences
- Vol. 9 (2) , 9-12
Evaluation of Vitamin B12 status in type 2 Diabetes Mellitus Patients on Metformin therapy
Background: B12 deficiency is a silent epidemic with serious consequences. Long term use of metformin has been associated with malabsorption of vitamin B12 leading to its deficiency along with increased homocysteine levels. With this background we designed this study to assess the status of vitamin B12 and its markers in type 2 diabetes mellitus patients on metformin therapy who are attending tertiary care hospital in the peripheral area of Pondicherry.Aims and Objective: The current study aims to study the relationship if any, between the glycemic status and the status of Vitamin B12 among T2DM patients on metformin therapy.Materials and Methods: A case control study was done with a sample size of 100 (50 case and 50 control). The patients were selected according to the inclusion criteria and their blood sample were analyzed for the various parameters. The markers of vitamin B12 status are studied among both the control and the patients with T2DM on metformin therapy and compared with their glycaemic status.Results: There is a significant increase in the levels of FBS, HbA1c, insulin and C-peptide in the study group. It was observed that the mean levels of homocysteine and Methylmalonic acid were significantly higher with lower levels of vitamin B12 in patients who were on metformin therapy.Conclusion: There is moderate correlation between the markers of B12 status and levels of fasting blood sugar as well as HbA1C. There is a significant correlation between insulin and C-peptide with the markers of vitamin B12 status.Asian Journal of Medical Sciences Vol.9(2) 2018 9-12
- 1 March 2018
- Published by Pharmamedix India Publication Pvt Ltd in Asian Journal of Medical Sciences
- Vol. 9 (2) , 9-12
Open AccessEvaluation of Vitamin B12 status in type 2 Diabetes Mellitus Patients on Metformin therapy
Background: B12 deficiency is a silent epidemic with serious consequences. Long term use of metformin has been associated with malabsorption of vitamin B12 leading to its deficiency along with increased homocysteine levels. With this background we designed this study to assess the status of vitamin B12 and its markers in type 2 diabetes mellitus patients on metformin therapy who are attending tertiary care hospital in the peripheral area of Pondicherry.Aims and Objective: The current study aims to study the relationship if any, between the glycemic status and the status of Vitamin B12 among T2DM patients on metformin therapy.Materials and Methods: A case control study was done with a sample size of 100 (50 case and 50 control). The patients were selected according to the inclusion criteria and their blood sample were analyzed for the various parameters. The markers of vitamin B12 status are studied among both the control and the patients with T2DM on metformin therapy and compared with their glycaemic status.Results: There is a significant increase in the levels of FBS, HbA1c, insulin and C-peptide in the study group. It was observed that the mean levels of homocysteine and Methylmalonic acid were significantly higher with lower levels of vitamin B12 in patients who were on metformin therapy.Conclusion: There is moderate correlation between the markers of B12 status and levels of fasting blood sugar as well as HbA1C. There is a significant correlation between insulin and C-peptide with the markers of vitamin B12 status.Asian Journal of Medical Sciences Vol.9(2) 2018 9-12
- Open Access
- 1 January 2018
- Published by Pharmamedix India Publication Pvt Ltd in Asian Journal of Medical Sciences
- Vol. 9 (1) , 11-14
A genetic perspective of Metformin induced Vitamin B12 deficiency in Type 2 Diabetes mellitus patients
Metformin, a commonly prescribed hypoglycemic agent is a first line medication for the management of Type 2 diabetes mellitus. Numerous studies have depicted that metformin therapy has been associated with vitamin B12 and folate deficiency. Vitamin B12 deficiency is frequently missed or misdiagnosed by the clinicians because it is not routinely tested by most of the physicians, further the low end of the laboratory reference range is too low and misinterpreted as diabetic peripheral neuropathy. Vitamin B12 deficiency is a silent epidemic with serious consequences. Long term use of metformin has been associated with increased homocysteine levels and malabsorption of vitamin B12 leading to its deficiency and neurological manifestations. Polymorphisms of certain genes associated with the metabolism of vitamin B12 and folate might help in predicting the deficiency status of vitamin B12.Asian Journal of Medical Sciences Vol.9(1) 2018 11-14
- 1 January 2018
- Published by Pharmamedix India Publication Pvt Ltd in Asian Journal of Medical Sciences
- Vol. 9 (1) , 11-14
Open AccessA genetic perspective of Metformin induced Vitamin B12 deficiency in Type 2 Diabetes mellitus patients
Metformin, a commonly prescribed hypoglycemic agent is a first line medication for the management of Type 2 diabetes mellitus. Numerous studies have depicted that metformin therapy has been associated with vitamin B12 and folate deficiency. Vitamin B12 deficiency is frequently missed or misdiagnosed by the clinicians because it is not routinely tested by most of the physicians, further the low end of the laboratory reference range is too low and misinterpreted as diabetic peripheral neuropathy. Vitamin B12 deficiency is a silent epidemic with serious consequences. Long term use of metformin has been associated with increased homocysteine levels and malabsorption of vitamin B12 leading to its deficiency and neurological manifestations. Polymorphisms of certain genes associated with the metabolism of vitamin B12 and folate might help in predicting the deficiency status of vitamin B12.Asian Journal of Medical Sciences Vol.9(1) 2018 11-14